Abbott Labs

ABT-N

NYSE:ABT

122.38
1.58 (1.31%)
Abbott Laboratories is a multinational health care company with headquarters in Lake Bluff, Illinois.
More at Wikipedia

Analysis and Opinions about ABT-N

Signal
Opinion
Expert
BUY
BUY
February 24, 2021
This can still go higher. No need to worry about their diabetes franchise.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 24, 2021
This can still go higher. No need to worry about their diabetes franchise.
PAST TOP PICK
PAST TOP PICK
February 18, 2021
(A Top Pick Oct 08/20, Up 17.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has achieved its $128 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $97) to the original recommended price level at $109.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 18, 2021
(A Top Pick Oct 08/20, Up 17.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has achieved its $128 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $97) to the original recommended price level at $109.
BUY
BUY
February 11, 2021
Diversified medical device company. Acquisitions increased leverage, but they've paid it down. Less focused on slower growth business, more on devices. Great quality. Positive results from Covid testing have exceeded estimates.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 11, 2021
Diversified medical device company. Acquisitions increased leverage, but they've paid it down. Less focused on slower growth business, more on devices. Great quality. Positive results from Covid testing have exceeded estimates.
BUY
BUY
January 22, 2021
They report Wednesday. They need to mass-produce their quick Covid test that the FDA approved. That said, he expects a beat from them because of progress in Abbott's blood-sugar monitor.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
January 22, 2021
They report Wednesday. They need to mass-produce their quick Covid test that the FDA approved. That said, he expects a beat from them because of progress in Abbott's blood-sugar monitor.
BUY
BUY
January 18, 2021
She still thinks it is as good long term investment in this space. Their testing kits are being widely deployed. Testing will remain an important factor in this COVID situation. They will still be well positioned. In their medical devices business they have a lot of new products that will be launched. The dividend is attractive and is increased annually. She sees good long term value.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
January 18, 2021
She still thinks it is as good long term investment in this space. Their testing kits are being widely deployed. Testing will remain an important factor in this COVID situation. They will still be well positioned. In their medical devices business they have a lot of new products that will be launched. The dividend is attractive and is increased annually. She sees good long term value.
BUY
BUY
October 15, 2020

ABT vs. JNJ Similar businesses. You absolutely need exposure to healthcare. He holds JNJ for the dividend aristocrat qualities. ABT has been impressive. Testing platform has been phenomenal and will continue to ramp up. It's a great addition to portfolios at these levels. Tough choice between the two, but ABT probably has more immediate upside.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
October 15, 2020

ABT vs. JNJ Similar businesses. You absolutely need exposure to healthcare. He holds JNJ for the dividend aristocrat qualities. ABT has been impressive. Testing platform has been phenomenal and will continue to ramp up. It's a great addition to portfolios at these levels. Tough choice between the two, but ABT probably has more immediate upside.

TOP PICK
TOP PICK
October 8, 2020
Stockchase Research Editor: Michael O'Reilly This medical device company has has been front and centre during the pandemic -- providing six COVID-19 test kits -- including one now that provides results in 15 minutes. The company's other products help patients with chronic cardiovascular, pulminary, and diabetic issues. The company is launching a new non-finger poking glucose monitoring device -- a game changer. A recent pullback in the share price gives an opportunity to enter with reasonable upside. We would trade this with a $97 stop-loss looking to achieve $128 -- 17% upside. Yield 1.34% (Analysts’ price target is $115.12)
Show full opinionHide full opinion
Abbott Labs (ABT-N)
October 8, 2020
Stockchase Research Editor: Michael O'Reilly This medical device company has has been front and centre during the pandemic -- providing six COVID-19 test kits -- including one now that provides results in 15 minutes. The company's other products help patients with chronic cardiovascular, pulminary, and diabetic issues. The company is launching a new non-finger poking glucose monitoring device -- a game changer. A recent pullback in the share price gives an opportunity to enter with reasonable upside. We would trade this with a $97 stop-loss looking to achieve $128 -- 17% upside. Yield 1.34% (Analysts’ price target is $115.12)
BUY
BUY
October 1, 2020
Their rapid covid test is positive. The company also has a lot of other great products, including interesting products for diabetes. The underlying fundamentals are strong. The equipment side of healthcare is more positive than the drug side.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
October 1, 2020
Their rapid covid test is positive. The company also has a lot of other great products, including interesting products for diabetes. The underlying fundamentals are strong. The equipment side of healthcare is more positive than the drug side.
BUY
BUY
September 30, 2020
Their new 15-minute Covid test rallied today. The test works with an app that indicates the user passing the test, hence allowing the user to board planes among other things. This could be a game-changer. This is still a buy despite today's rally.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
September 30, 2020
Their new 15-minute Covid test rallied today. The test works with an app that indicates the user passing the test, hence allowing the user to board planes among other things. This could be a game-changer. This is still a buy despite today's rally.
PAST TOP PICK
PAST TOP PICK
September 15, 2020
(A Top Pick Sep 12/19, Up 28%) Still buying it around $102. It's a diversified healthcare company including nutritionals and generic drugs, the latter being sold to emerging markets. EM account for 40% of revenues. Medical devices was seeing fine product momentum even before Covid. After Covid, they've been producing testing kits which drives growth. They just announced a 5-minute test, boasting easy-to-use packaging, which will push growth. She expects excellent growth in the next few years, and it pays a solid dividend.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
September 15, 2020
(A Top Pick Sep 12/19, Up 28%) Still buying it around $102. It's a diversified healthcare company including nutritionals and generic drugs, the latter being sold to emerging markets. EM account for 40% of revenues. Medical devices was seeing fine product momentum even before Covid. After Covid, they've been producing testing kits which drives growth. They just announced a 5-minute test, boasting easy-to-use packaging, which will push growth. She expects excellent growth in the next few years, and it pays a solid dividend.
BUY
BUY
July 27, 2020
Biotech has been strong, so steer away from this and go to pharma. Abbot is on the verge of breaking out after basing. There's potential with their vaccine. Pays around 1.5% dividend. He doesn't expect politicians to pressure pharma stocks during this pandemic.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
July 27, 2020
Biotech has been strong, so steer away from this and go to pharma. Abbot is on the verge of breaking out after basing. There's potential with their vaccine. Pays around 1.5% dividend. He doesn't expect politicians to pressure pharma stocks during this pandemic.
WATCH
WATCH
July 22, 2020
The pharma sector has been a safe haven during the pandemic. With companies involved with COVID research, he is looking at this closely. He does not own it yet. They have great dividends, but growth has been slow and that problem will not go away anytime soon. Having exposure to pharma would be a good thing.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
July 22, 2020
The pharma sector has been a safe haven during the pandemic. With companies involved with COVID research, he is looking at this closely. He does not own it yet. They have great dividends, but growth has been slow and that problem will not go away anytime soon. Having exposure to pharma would be a good thing.
TOP PICK
TOP PICK
June 24, 2020
She is putting new client money into this last week. A diversified health care company with four divisions. They have a pharma group that sells into emerging markets. They also have a medical device, diagnostics and a nutritional division. They have developed both screening and antibody tests for COVID-19. Even if a vaccine is found, testing will be required for quite a while. They have increased their dividend for over 40 consecutive years. Yield 1.62% (Analysts’ price target is $100.75)
Show full opinionHide full opinion
Abbott Labs (ABT-N)
June 24, 2020
She is putting new client money into this last week. A diversified health care company with four divisions. They have a pharma group that sells into emerging markets. They also have a medical device, diagnostics and a nutritional division. They have developed both screening and antibody tests for COVID-19. Even if a vaccine is found, testing will be required for quite a while. They have increased their dividend for over 40 consecutive years. Yield 1.62% (Analysts’ price target is $100.75)
COMMENT
COMMENT
June 18, 2020

ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
June 18, 2020

ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.

PAST TOP PICK
PAST TOP PICK
May 13, 2020
(A Top Pick May 14/19, Up 25%) They have held this for years. Their diagnostic division has developed four different COVID testing products, including tests for antibodies. Their recent earnings reflect delays in device growth, which she was not surprised with. However, the diagnostics division is ramping up and benefiting with all the upcoming test requirements. She has been adding to portfolios around $90.
Show full opinionHide full opinion
Abbott Labs (ABT-N)
May 13, 2020
(A Top Pick May 14/19, Up 25%) They have held this for years. Their diagnostic division has developed four different COVID testing products, including tests for antibodies. Their recent earnings reflect delays in device growth, which she was not surprised with. However, the diagnostics division is ramping up and benefiting with all the upcoming test requirements. She has been adding to portfolios around $90.
Showing 1 to 15 of 136 entries

Abbott Labs(ABT-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 12

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 12

Stockchase rating for Abbott Labs is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Abbott Labs(ABT-N) Frequently Asked Questions

What is Abbott Labs stock symbol?

Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N

Is Abbott Labs a buy or a sell?

In the last year, 12 stock analysts published opinions about ABT-N. 12 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Abbott Labs.

Is Abbott Labs a good investment or a top pick?

Abbott Labs was recommended as a Top Pick by Jim Cramer - Mad Money on 2021-02-24. Read the latest stock experts ratings for Abbott Labs.

Why is Abbott Labs stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Abbott Labs worth watching?

12 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.

What is Abbott Labs stock price?

On 2021-02-24, Abbott Labs (ABT-N) stock closed at a price of $122.38.